Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Recruiting now

Conditions studied: Schizophrenia

In brief

The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

Key facts

Study ID

NCT07379827

Run by

Bristol-Myers Squibb

People needed

1500

Starts

2026-02-26

Expected to finish

2028-06-20

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants (or caregiver/legal guardian) must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written ICF or signed an electronic ICF in accordance with regulatory, local, and institutional guidelines.
• Adults ≥ 18 years of age at Baseline who are willing and able, in the judgement of the treating clinician, to participate in routine clinical care and follow up.
• Schizophrenia, confirmed by the treating clinician's judgement or physician decision to treat the patient with receiving xanomeline and trospium chloride (KarXT) for schizophrenia made prior to and independently of participation in this study. Current Antipsychotic Treatment: Participant must fall into one of the categories below:
• Be within <16 weeks of initiating treatment with KarXT with intent to discontinue prior antipsychotic treatment(s) OR
• On a stable regimen (dose and frequency consistent with the drug label and/or at a stable dose based on the judgement of the Investigator for at least 30 days prior to screening) of treatment with 1 or more antipsychotics with plan to discontinue and switch to treatment with KarXT from a prior antipsychotic treatments(s). NOTE: The decision to switch for reasons of safety, tolerability, and/or efficacy will be made independently by the treating clinician and/or the patient and is not dictated by the study. Participants can be enrolled during tapering/discontinuing process from prior antipsychotic treatment(s). Individuals who are not currently receiving treatment for schizophrenia are not eligible for the study. Any antipsychotic treatments must be recorded as concomitant medications.
• Concomitant psychiatric medications (eg, antidepressants, mood stabilizers, anxiolytics) are permitted and are recommended to remain at a stable dose during the study period.

You may not qualify if…

• Prior use of KarXT that has been discontinued for any reason prior to Baseline.
• Participation in an interventional study within the last 30 days or plans to participate in an interventional study at the time of eligibility or baseline through the study period.
• Known hypersensitivity to xanomeline or trospium chloride, or history or high risk of urinary retention, gastric retention, moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment, or narrow-angle glaucoma.
• In the opinion of the treating clinician, unstable psychiatric or medical conditions that would prevent the participant from safely switching to KarXT. Hospitalized individuals who have been switched to KarXT or are switching treatment to KarXT are permitted to be enrolled at discharge if they are < 16 weeks from initiation of KarXT.
• Participants who are pregnant, planning to become pregnant, or breastfeeding.

Where it is running

• Psychiatric Consultants, Pc — Franklin, Tennessee, United States (enrolling)
• BioResearch Partner - Miami — Miami, Florida, United States (enrolling)
• Perelman School of Medicine at the University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
• Pioneer Research Solutions, Inc. — Houston, Texas, United States (enrolling)
• Galiz Research — Hialeah, Florida, United States (enrolling)
• Medical Research of Central Florida — Orange City, Florida, United States (enrolling)
• SanRo Clinical Research Group — Bryant, Arkansas, United States (enrolling)
• The Rivus Wellness & Research Institute — Oklahoma City, Oklahoma, United States (enrolling)
• Perceptive Pharma Research — Richmond, Texas, United States (enrolling)
• New Access Research & Medical Services Inc - Kendall — Kendall, Florida, United States (enrolling)
• PPD Virtual - PPD - US — Wilmington, North Carolina, United States (enrolling)
• Banyan Behavioal Care Program - CSU — Miami, Florida, United States (enrolling)
• Envision Trials LLC — Bonita Springs, Florida, United States (enrolling)
• Local Institution - 0007 — Miami, Florida, United States
• Local Institution - 0028 — Stanford, California, United States
• Local Institution - 0032 — Miami, Florida, United States
• Local Institution - 0043 — Oceanside, California, United States
• Local Institution - 0003 — Anaheim, California, United States
• Local Institution - 0048 — Warrenville, Illinois, United States
• Local Institution - 0046 — Crystal Lake, Illinois, United States
• Local Institution - 0044 — Marietta, Georgia, United States
• Local Institution - 0014 — Bloomfield Township, Michigan, United States
• Local Institution - 0036 — Detroit, Michigan, United States
• Local Institution - 0034 — Apple Valley, Minnesota, United States
• Local Institution - 0030 — Homestead, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.